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Introduction
Ifosfamide (IFO) is an oxazaphosphorine alkylating agent which 
is commonly used in cancer chemotherapy and immunosuppres-
sive protocols.1 Unfortunately, the optimal clinical usefulness of 
IFO is severely limited by a high incidence of nephrotoxicity in 
the form of Fanconi Syndrome especially in children.2,3 It is well 
documented that IFO is a prodrug that must be biotransformed 
by hepatic cytochrome P450 system to produce the active alkylat-
ing species, isophosphoramide mustard (IPM) and the urotoxic 
metabolite, acrolein, the main cause of hemorrhagic cystitis.1,3 
IFO also undergoes N-dechloroethylation pathway to produce 
the toxic metabolites, 2 and 3-dechloroethylated compounds as 
In addition to hemorrhagic cystitis, Fanconi syndrome is a serious clinical side effect during ifosfamide (IFO) therapy. 
Fanconi syndrome is a generalized dysfunction of the proximal tubule which is characterized by excessive urinary 
excretion of glucose, phosphate, bicarbonate, amino acids and other solutes excreted by this segment of the nephron 
including L-carnitine. Carnitine is essential cofactor for β-oxidation of long-chain fatty acids in the myocardium. IFO 
therapy is associated with increased urinary carnitine excretion with subsequent secondary deficiency of the molecule. 
Cardiac abnormalities in IFO-treated cancer patients were reported as isolated clinical cases. This study examined 
whether carnitine deficiency and oxidative stress, secondary to Fanconi syndrome, provoke IFO-induced cardiomyopathy 
as well as exploring if carnitine supplementation using propionyl-L-carnitine (pLC) could offer protection against this 
toxicity. In the current study, an animal model of carnitine deficiency was developed in rats by D-carnitine-mildronate 
treatment Adult male Wistar albino rats were assigned to one of six treatment groups: the first three groups were injected 
intraperitoneally with normal saline, D-carnitine (DC, 250 mg/kg/day) combined with mildronate (MD, 200 mg/kg/day) 
and pLC (250 mg/kg/day), respectively, for 10 successive days. The 4th, 5th and 6th groups were injected with the same 
doses of normal saline, DC-MD and pLC, respectively for 5 successive days before and 5 days concomitant with IFO   
(50 mg/kg/day). IFO significantly increased serum creatinine, blood urea nitrogen (BUN), urinary carnitine excretion and 
clearance, creatine phosphokinase isoenzyme (CK-MB), lactate dehydrogenase (LDh), intramitochondrial acetyl-CoA/
CoA-sh and thiobarbituric acid reactive substances (TBARs) in cardiac tissues and significantly decreased adenosine 
triphosphate (ATp) and total carnitine and reduced glutathione (Gsh) content in cardiac tissues. In carnitine-depleted 
rats, IFO induced dramatic increase in serum creatinine, BUN, CK-MB, LDh, carnitine clearance and intramitochondrial 
acetyl-CoA/CoA-sh, as well as progressive reduction in total carnitine and ATp in cardiac tissues. Interestingly, pLC 
supplementation completely reversed the biochemical changes-induced by IFO to the control values. In conclusion, 
data from the present study suggest that: Carnitine deficiency and oxidative stress, secondary to Fanconi syndrome, 
constitute risk factors and should be viewed as mechanisms during development of IFO-induced cardiotoxicity. Carnitine 
supplementation, using pLC, prevents the development of IFO-induced cardiotoxicity through antioxidant signalling and 
improving mitochondrial function.
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well as chloroacetaldehyde (CAA), a substance that decomposed 
to give another potential toxic compound thiodiaglycolic acid 
(TDGA). Earlier and recent studies reported that IFO therapy 
is associated with severe nephrotoxicity.4,5 It has been reported 
that local formation and accumulation of CAA in human kidney 
is the major cause of IFO-induced nephrotoxicity.6-8 In isolated 
rat kidney mitochondria, Nissim et al. reported that CAA inhib-
its NADH: ubiquinone oxidoreductase which disrupts oxidative 
phosphorylation, leading to multiple metabolic abnormalities, 
including elevation of NADH, decrease pyruvate dehydrogenase 
reaction and TCA cycle.7 Hence, despite the co-administration of 
mesna which has low reactivity with CAA, treatment with IFO 
is associated with severe proximal tubular dysfunction in the www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  267
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regimen on serum, urine and cardiac carnitine levels in normal 
and carnitine depleted rats and its relationship to IFO-induced 
cardiotoxicity. The second aim was to gain insights into the 
possibility of mechanism-based protection of the heart by PLC 
against side effects of IFO.
Results
Table 1 shows the effects of IFO on serum creatinine and BUN 
in PLC-supplemented and carnitine-depleted rats. IFO resulted 
in a highly significant 233 and 155%, increase in serum creati-
nine and BUN, respectively as compared to control. Treatment 
with DC-MD for 5 days before and 5 days concomitant with 
IFO resulted in a significant 53 and 102% increase in the levels 
of serum creatinine and BUN, respectively as compared to IFO 
alone. Interestingly, administration of PLC 5 days before and 5 
days concomitant with IFO resulted in complete reversal of the 
increases in serum creatinine and BUN to the control values.
The effects of IFO on urinary carnitine excretion and car-
nitine clearance in PLC-supplemented and carnitine-depleted 
rats are shown in Table 2. Administration of IFO (50 mg/kg/
day) for 5 days resulted in 2- and 2.3-folds increase in carnitine 
excretion and clearance, respectively, as compared to the control 
group. Treatment of carnitine-depleted rats with IFO resulted in 
a significant increase in both excretion and clearance of carni-
tine, as compared to IFO alone. Carnitine supplementation by 
daily administration of PLC for 5 days before and 5 days con-
comitant with IFO resulted in 1.8- and 0.8-folds increase in car-
nitine excretion and clearance, respectively, as compared to the 
Table 1. effect of ifosfamide (IFO), propionyl-l-carnitine (pLC),  
D-carnitine-mildronate (DC-MD) and their combination on serum 
creatinine and blood urea nitrogen (BUN) in rats
Treatment groups Serum creatinine (mg/dl) BUN (mg/dl)
Control 0.57 ± 0.04 52 ± 1.43
DC-MD 0.57 ± 0.04 60 ± 2.34
pLC 0.54 ± 0.04 46 ± 3.18
IFO 1.9 ± 0.22* 133 ± 8.92*
IFO plus DC-MD 2.9 ± 0.24*$ 277 ± 16.5*$
IFO plus pLC 0.94 ± 0.15# 57 ± 1.43#
Rats were randomly divided into six different groups of 10 animals 
each: Control, D-carnitine-mildronate (DC-MD, carnitine-depleted 
group), pLC (carnitine supplemented group), IFO, DC-MD plus IFO and 
pLC plus IFO. Carnitine depletion was induced in rats by daily intraperi-
toneal injection of DC (250 mg/kg/day) combined with MD (200 mg/kg/
day) for 10 successive days. Carnitine supplementation was induced in 
rats by daily intraperitoneal injection of pLC (250 mg/kg/day) for 10 suc-
cessive days. Fanconi syndrome was induced in rats by administration 
of IFO (50 mg/kg/day, I.p.) for 5 successive days. IFO-carnitine depleted 
rats were given the same doses of DC-MD for 5 days before and 5 days 
concomitant with IFO. IFO-carnitine supplemented rats were given 
the same doses of pLC for 5 days before and 5 days concomitant with 
IFO. At the end of the treatment protocol, serum creatinine and BUN, 
indices of nephrotoxicity, were measured in serum. Data are presented 
as mean ± s.e.M. (n = 10). *, # and $ indicate significant change from 
control, IFO and DC-MD respectively, at p < 0.05 using ANOVA followed 
by Tukey–Kramer as a post ANOVA test.
Table 2. effect of ifosfamide (IFO), propionyl-l-carnitine (pLC), D-car-
nitine-mildronate (DC-MD) and their combination on urinary carnitine 
excretion and carnitine clearance in rats
Treatment groups
Urinary carnitine 
excretion (µmol/day)
Carnitine clearance 
(ml/min) x 10-2
Control 0.53 ± 0.06 0.85 ± 0.14
DC-MD 2.78 ± 0.50* 9.75 ± 2.66*
pLC 10.06 ± 0.88* 6.97 ± 066*
IFO 1.61 ± 0.11 3.50 ± 0.78*
IFO plus DC-MD 4.17 ± 0.68*#$ 9.39 ± 1.42*#
IFO plus pLC 4.53 ± 1.79*# 4.52 ± 2.14*
Rats were randomly divided into 6 different groups of 10 animals each: 
Control, D-carnitine-mildronate (DC-MD, carnitine-depleted group), 
pLC (carnitine supplemented group), IFO, DC-MD plus IFO and pLC plus 
IFO. Carnitine depletion was induced in rats by daily intraperitoneal 
injection of DC (250 mg/kg/day) combined with MD (200 mg/kg/day) 
for 10 successive days. Carnitine supplementation was induced in rats 
by daily intraperitoneal injection of pLC (250 mg/kg/day) for 10 succes-
sive days. Fanconi syndrome was induced in rats by administration of 
IFO (50 mg/kg/day, I.p.) for 5 successive days. IFO-carnitine depleted 
rats were given the same doses of DC-MD for 5 days before and 5 days 
concomitant with IFO. IFO-carnitine supplemented rats were given the 
same doses of pLC for 5 days before and 5 days concomitant with IFO. 
At the end of the treatment protocol, carnitine excretion and clearance 
were measured in 24 hours urine. Data are presented as mean ± s.e.M. 
(n = 10). *, # and $ indicate significant change from control, IFO and DC-
MD respectively, at p < 0.05 using ANOVA followed by Tukey–Kramer as 
a post ANOVA test.
form of Fanconi Syndrome, which is characterized by excessive   
urinary excretion of glucose, phosphate, bicarbonate, amino 
acids and other solutes handled by this segment of the nephron 
including L-carnitine.9,10
L-Carnitine is an endogenous compound that plays an impor-
tant physiological role in the transfer of long-chain fatty acids 
across the inner membrane of mitochondria for their β-oxidation 
and energy production.11 Kidney plays an important role in keep-
ing the homeostasis of carnitine by conserving 95% of the fil-
tered carnitine.12 The tubular reabsorption is compromised in 
IFO-treated patients suffering from nephrotoxicity thus, high 
renal loss of the compound persisted during the treatment.13 In 
addition, it is well documented that cachectic cancer patients are 
especially at risk for carnitine deficiency due to decreased intesti-
nal absorption and increased renal losses.14-18 It has been reported 
that IFO therapy is associated with increased secretion of carni-
tine derivatives in the urine with subsequent secondary deficiency 
of the molecule.13 It is well documented that CAA and TDGA, 
the two major toxic metabolites of IFO, inhibit the oxidation of 
long-chain fatty acids (carnitine-dependent) but not medium 
chain-fatty acids (carnitine-independent) indicating that these 
compounds either sequester carnitine or inhibit long-chain fatty 
acid oxidation by inhibition of carnitine palmitoyl transferase-I 
(CPT I).6,19 Although kidney is the main organ responsible for 
endogenous synthesis of L-carnitine, up to date in the literature, 
we could not find any study investigating the effects of IFO on 
renal handling of carnitine and its metabolic consequences on the 
myocardium under condition of carnitine depletion and supple-
mentation. Therefore, this study has been initiated to investi-
gate the effects of the standard IFO-induced Fanconi Syndrome 268  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 4
rats resulted in a significant 64 and 33% decrease in CoA-SH 
level in isolated rat heart mitochondria, thus raising the ratio to 
52 and 41% as compared to the results of the control and IFO 
groups, respectively. Interestingly, daily administration of PLC to 
IFO-treated rats resulted in a complete reversal of IFO-induced 
changes in CoA-SH and aceyl-CoA/CoA-SH level in mitochon-
dria to the control values.
Table 4 shows the effects of IFO on oxidative stress biomark-
ers, TBARS and GSH in cardiac tissues. IFO produced GSH 
nadir amounted to 60% and dramatically elevated the TBARS 
levels in cardiac tissues by 80% compared to control group. 
Repeated administration of DC-MD followed by IFO resulted 
in a significant 29 and 223% increase in the level of GSH in car-
diac tissues as compared to the control and IFO groups, respec-
tively. On the other hand, the treatment modality resulted in a 
significant 44% decrease in the level of TBARS in cardiac tissues 
as compared to IFO group. Pre-treatment with PLC followed by 
IFO challenge thereafter resulted in a complete reversal of IFO-
induced increase in TBARS and decrease in GSH level in cardiac 
tissues to the control values.
Discussion
Recent studies in our laboratory20-24 and others25,26 have demon-
strated the progression of cisplatin, carboplatin, cyclophospha-
mide and gentamicin-induced nephrotoxicity, cardiomyopathy 
control values. Administration of DC-MD for 10 successive days 
resulted in a significant 4- and 10.5-folds increase as compared to 
the control group.
Table 3 shows the effects of IFO on the activity of serum 
CK-MB and LDH, in PLC-supplemented and carnitine-depleted 
rats. Administration of IFO resulted in a significant 49 and 79% 
increase in serum CK-MB and LDH, respectively, as compared 
to the control group. Treatment with either PLC (carnitine-
supplemented rats) or combined DC-MD (carnitine-depleted 
rats) for 10 successive days showed non-significant changes. 
Treatment with DC-MD for 5 days before and 5 days concomi-
tant with IFO resulted in a significant 54% increase in the activ-
ity of CK-MB and 12% elevation in LDH as compared to IFO 
alone. Interestingly, administration of PLC for 5 days before and 
5 days after IFO resulted in a complete reversal of IFO-induced 
increase in serum CK-MB and LDH to the control values.
Figure 1 shows the effects of IFO on the levels of total carni-
tine in serum (Fig. 1A), total carnitine in cardiac tissues (Fig. 1B) 
and ATP concentration in cardiac tissues (Fig. 1C) from PLC-
supplemented and carnitine-depleted rats. Administration of 
PLC for 10 successive days resulted in a significant 126% increase 
in serum total carnitine, whereas, administration of DC-MD for 
10 successive days resulted in a non-significant change as com-
pared to the control group. Treatment with IFO resulted in non 
significant changes in serum carnitine level as compared to the 
results of the control group. Treatment with DC-MD for 5 days 
before and 5 days concomitant with IFO decreased serum car-
nitine levels as compared to the results of the control, IFO and 
DC-MD groups. Interestingly, daily administration of PLC for 
5 days before and 5 days concomitant with IFO resulted in a sig-
nificant 87 and 91% increase in serum carnitine as compared to 
the results of the control and IFO groups, respectively.
On the other hand, IFO alone resulted in a significant 45% 
decrease in total carnitine level in cardiac tissues, while admin-
istration of DC-MD alone caused a significant 42% decrease as 
compared to the control group. Combined treatment with IFO 
and DC-MD resulted in a significant 90, 82 and 80% decrease in 
the total carnitine level in cardiac tissues as compared to the con-
trol, DC-MD and IFO groups, respectively. Moreover, challeng-
ing with IFO alone significantly decreased ATP levels by 52% in 
cardiac tissues as compared to control. Carnitine-depleted rats 
showed significant 45% reduction in cardiac ATP levels, while 
combining modality also lowered the ATP content by about 86, 
74 and 72% compared to either control, DC-MD and IFO given 
alone, respectively. Interestingly, carnitine supplementation by 
daily administration of PLC to animals receiving IFO resulted 
in a complete reversal of IFO-induced decrease in total carnitine 
and ATP levels in cardiac tissues to the control values.
Figure 2 shows the effects of IFO on the level of CoA-SH 
(Fig. 2A), acetyl-CoA (Fig. 2B) and acetyl-CoA/CoA-SH (Fig. 
2C) in heart mitochondria isolated from carnitine depleted and 
supplemented rats. Treatment with previously mentioned regi-
men of IFO and DC-MD resulted in a significant 46 and 26% 
decrease in CoA-SH level and a significant 79 and 57% increase 
in acetyl-CoA/CoA-SH ratio as compared to the control and IFO 
groups, respectively. Administration of IFO to carnitine-depleted 
Table 3. effect of ifosfamide (IFO), propionyl-l-carnitine (pLC), D-
carnitine-mildronate (DC-MD) and their combination on serum creatine 
phosphokinase isoenzyme (CK-MB) and lactate dehydrogenase (LDh) 
in rats.
Treatment groups CK-MB (U/L) LDH (U/L)
Control 353.60 ± 8.06 344.47 ± 19.60
DC-MD 464.67 ± 27.43 440.40 ± 23.96
pLC 308.40 ± 19.87 348.40 ± 25.83
IFO 547.01 ± 21.40* 616.80 ± 23.20*
IFO plus DC-MD 733.80 ± 35.10*$ 695.60 ± 40.01*$
IFO plus pLC 351.42 ± 21.80# 432.60 ± 23.60#
Rats were randomly divided into 6 different groups of 10 animals each: 
Control, D-carnitine-mildronate (DC-MD, carnitine-depleted group), 
pLC (carnitine supplemented group), IFO, DC-MD plus IFO and pLC plus 
IFO. Carnitine depletion was induced in rats by daily intraperitoneal 
injection of DC (250 mg/kg/day) combined with MD (200 mg/kg/day) 
for 10 successive days. Carnitine supplementation was induced in rats 
by daily intraperitoneal injection of pLC (250 mg/kg/day) for 10 succes-
sive days. Fanconi syndrome was induced in rats by administration of 
IFO (50 mg/kg/day, I.p.) for 5 successive days. IFO-carnitine depleted 
rats were given the same doses of DC-MD for 5 days before and 5 days 
concomitant with IFO. IFO-carnitine supplemented rats were given 
the same doses of pLC for 5 days before and 5 days concomitant with 
IFO. At the end of the treatment protocol, CK-MB and LDh, indices of 
cardiotoxicity, were measured in serum. Data are presented as mean 
± s.e.M. (n = 10). *, # and $ indicate significant change from control, IFO 
and DC-MD respectively, at p < 0.05 using ANOVA followed by Tukey-
Kramer as a post ANOVA test. Data are presented as mean ± s.e.M. (n = 
10). *, # and $ indicate significant change from control, IFO and DC-MD 
respectively, at p < 0.05 using ANOVA followed by Tukey-Kramer as a 
post ANOVA test.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  269
doses of the alkylating drugs cyclophosphamide and IFO may 
result in a reversible heart failure and life-threatening arrhyth-
mias.34-36 Cardiac effects reported with IFO therapy include 
supraventricular arrhythmias,29 ventricular premature contrac-
tion, dilated cardiomyopathy33 and severe refractory congestive 
heart failure.7,9,10 In this context, the current study addressed the 
possible contribution of carnitine deficiency as a risk factor in 
IFO-induce cardiotoxicity.
Data presented here demonstrated that IFO increased serum 
LDH and CK-MB. This increase in cardiac enzymes could be 
due to IFO-induced generation of reactive oxygen species (ROS) 
and lipid peroxidation of cardiac membranes with the conse-
quent leakage of these enzymes from damaged myocytes. The 
contribution of oxidative and nitrosative stress in IFO and cyclo-
phosphamide-induced multiple organ toxicity has been recently 
reported.36-38 It is well documented that ROS and oxidative 
stress play an important role in organ dysfunction induced by 
anticancer drugs.39,40 Increased oxidative stress biomarkers and 
and hepatotoxicity under condition of carnitine deficiency and 
that carnitine supplementation attenuates these multiple organ 
toxicity. Although it is well documented that IFO therapy is asso-
ciated with Fanconi Syndrome,7,9,10 we could not find any study 
investigating the effects of IFO on renal handling of carnitine 
and its metabolic consequences under condition of carnitine 
depletion and supplementation. Taken together, this prompted 
us to investigate, for the first time, whether carnitine deficiency 
secondary to IFO-induced Fanconi Syndrome plays a role and 
should be viewed as a risk factor during development of IFO-
induced cardiomyopathy as well as exploring if carnitine supple-
mentation using PLC could offer protection against this toxicity.
Results from this study demonstrated that IFO increased 
nephrotoxicity indices, serum creatinine (233%) and BUN 
(155%) which precipitates IFO-induced Fanconi Syndrome. 
Under similar experimental condition, several studies reported 
that administration of IFO (50 mg/kg) for 5 successive days is 
associated with severe nephrotoxicity in the form of Fanconi 
Syndrome.7,9,10 In carnitine depleted rats, IFO caused progres-
sive increase in BUN and serum creatinine which was parallel to 
the marked increase in urinary carnitine excretion and clearance 
(Tables 1 and 2). This effect could be due to carnitine deficiency 
with subsequent impairment of fatty acid oxidation and shift-
ing metabolism into carnitine-independent or non-lipid energy 
substrates. This speculation is consistent with data presented by 
Ahmed, et al. which reported that carnitine supplementation to 
patients undergoing hemodialysis decreased protein catabolism, 
thereby, reducing serum concentration of the products of protein 
catabolism, including BUN and creatinine.27
Cardiotoxicity occurs during therapy with several cytotoxic 
drugs and may be the dose limiting factor in cancer treatment. It 
can be responsible for long term side effects causing severe mor-
bidity in surviving cancer patients.28 Although IFO has not been 
added to the list of antineoplastic therapies associated with major 
cardiac complications, its cardiotoxicity was reported as isolated 
clinical cases in cancer patients receiving IFO in combination 
with other anticancer drugs.29-33 It has been reported that high 
Figure 1. effect of ifosfamide (IFO) on the levels of total carnitine in 
serum (A), total carnitine in cardiac tissues (B) and ATp concentration in 
cardiac tissues (C) from propionyl-l-carnitine (pLC)-supplemented and 
carnitine-depleted rats. Rats were randomly divided into 6 different 
groups of 10 animals each: Control, D-carnitine-mildronate (DC-MD, 
carnitine-depleted group), pLC (carnitine supplemented group), IFO, 
DC-MD plus IFO and pLC plus IFO. Carnitine depletion was induced in 
rats by daily intraperitoneal injection of DC (250 mg/kg/day) combined 
with MD (200 mg/kg/day) for 10 successive days. Carnitine supplemen-
tation was induced in rats by daily intraperitoneal injection of pLC (250 
mg/kg/day) for 10 successive days. Fanconi syndrome was induced in 
rats by administration of IFO (50 mg/kg/day, I.p.) for 5 successive days. 
IFO-carnitine depleted rats were given the same doses of DC-MD for 
5 days before and 5 days concomitant with IFO. IFO-carnitine supple-
mented rats were given the same doses of pLC for 5 days before and 5 
days concomitant with IFO. At the end of the treatment protocol, total 
carnitine was measured in serum whereas ATp and total carnitine were 
measured in cardiac tissues. Data are presented as mean ± s.e.M. (n = 
10). *, # and $ indicate significant change from control, IFO and DC-MD 
respectively, at p < 0.05 using ANOVA followed by Tukey-Kramer as a 
post ANOVA test.270  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 4
depletion of enzymatic and non-enzymatic antioxidants have 
been reported in cardiopulmonary and other metabolic disor-
ders.41 Fascinatingly, administration of PLC for 5 days before and 
5 days concomitant with IFO completely prevented the increase 
in LDH and CK-MB induced by IFO, suggesting that PLC may 
have potential protective effect against IFO-induced cardiac 
damage. This effect could be due to cardiac membrane stabili-
zation by the L-carnitine portion of PLC which interacts with 
sarcolemmal phospholipids and mitochondrial membranes42 
with subsequent decrease in the release of cardiac enzymes. 
Moreover, PLC through its reported antioxidant defence in the 
heart and other tissues could protect myocytes against IFO-
induced lipid peroxidation.43 The antioxidant effect of PLC has 
been confirmed by our results which have reported that PLC 
induced complete reversal of IFO-induced increase in TBARS 
and decrease in GSH in cardiac tissues to the control values. 
More recently, the antioxidant and anti-inflammatory effects of 
L-carnitine and PLC have been reported.35,44 In contrast, admin-
istration of IFO to carnitine-depleted rats produced a progressive 
increase in the activities of LDH and CK-MB. It is reported that 
IFO treatment is associated with nephrotoxicity in the form of 
Fanconi Syndrome.7,9,10 The IFO regimen used in current study 
(50 mg/kg/day) for 5 successive days proves to be nephrotoxic as 
evidenced by the increase in serum creatinine and BUN in rats. 
Quezado, et al. reported that development of congestive heart 
failure in patients with lymphoma was significantly correlated 
with the doubling in serum creatinine after IFO treatment.31 Our 
results are unique since no available experimental or clinical data 
about the role of endogenous carnitine system during develop-
ment of IFO-induced multiple organ toxicity.
In the current study, the observed decrease in cardiac carni-
tine content could be a secondary event following IFO-induced 
inhibition of endogenous synthesis and/or inhibition of tubu-
lar reabsorption of carnitine. Since kidney is the major site for 
endogenous carnitine biosynthesis and 95% of filtered carnitine 
is reabsorbed by the proximal tubules of the nephron, there-
fore, IFO-induced Fanconi Syndrome may lead to inhibition of 
endogenous carnitine biosynthesis and increases its urinary losses 
with the consequent secondary deficiency of the molecule. This 
is in line with current data which showed that urinary carnitine 
excretion and carnitine clearance were increased by administra-
tion of IFO. The present results are in line with the only clinical 
study performed on five patients and reported that IFO increased 
urinary carnitine excretion.13 These results are in good agree-
ment with earlier and recent studies which have reported that 
increased urinary excretion of carnitine is an early marker in 
chemotherapy-induced nephrotoxicity.25,45,46 Moreover, the role 
of IFO metabolites in kidney and heart damage cannot be ruled 
out. Inhibition of the oxidation of long-chain fatty acids by CAA 
and TDGA has been previously reported.6,19
Data reported here demonstrate that IFO administration 
significantly decreased intramitochondrial free CoA-SH, an 
indispensable activator in Kreb’s cycle and β-oxidation. This 
effect could be explained on the basis of the high reactivity of 
IFO metabolites including CAA, TDGA, IPM and acrolin, with 
SH-containg molecules. Earlier studies have documented that the 
Figure 2. effect of ifosfamide (IFO), propionyl-l-carnitine (pLC), D-
carnitine-mildronate (DC-MD) and their combination on the levels of 
CoA-sh (A), acetyl-CoA (B) and acetyl-CoA/CoA-sh (C) in isolated rat 
heart mitochondria. Rats were randomly divided into 6 different groups 
of 10 animals each: Control, D-carnitine-mildronate (DC-MD, carnitine-
depleted group), pLC (carnitine supplemented group), IFO, DC-MD plus 
IFO and pLC plus IFO. Carnitine depletion was induced in rats by daily 
intraperitoneal injection of DC (250 mg/kg/day) combined with MD 
(200 mg/kg/day) for 10 successive days. Carnitine supplementation was 
induced in rats by daily intraperitoneal injection of pLC (250 mg/kg/day) 
for 10 successive days. Fanconi syndrome was induced in rats by admin-
istration of IFO (50 mg/kg/day, I.p.) for 5 successive days. IFO-carnitine 
depleted rats were given the same doses of DC-MD for 5 days before 
and 5 days concomitant with IFO. IFO-carnitine supplemented rats were 
given the same doses of pLC for 5 days before and 5 days concomitant 
with IFO. At the end of the treatment protocol, rat hear mitochondria 
was isolated for measurement of CoA-sh, acetyl-CoA and CoA-sh/
acetyl-CoA ratio. Data are presented as mean ± s.e.M. (n = 10). *, # and $ 
indicate significant change from control, IFO and DC-MD respectively, at 
p < 0.05 using ANOVA followed by Tukey-Kramer as a post ANOVA test.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  271
In the current study, utilizing PLC as a source of carnitine pre-
vented IFO and DC-MD induced decrease in cardiac carnitine 
content, intramitochondrial CoA-SH and ATP production by 
replenishing the myocardium with adequate carnitine for energy 
production. A possible explanation for this is that, in the mito-
chondria, PLC has higher affinity for CoA-SH:carnitine acetyl-
transferase (CAT) and being metabolized into free L-carnitine 
and propionyl-CoA.49,50 The L-carnitine portion of PLC will 
increase fatty acid oxidation by increasing its mitochondrial 
transport through CPT-I and/or decreasing the intramitochon-
drial acetyl-CoA/CoA-SH ratio. The propionyl-CoA formed in 
mitochondria from PLC metabolism will stimulate substrates 
oxidation since it can be converted into succinyl-CoA in a reac-
tion mediated by propionyl-CoA carboxylase, thus increasing 
the flux of acetyl-CoA through TCA cycle. In summary, this 
study suggests that IFO is usually associated in the setting of 
nephrotoxicity and increased urinary carnitine loss, with severe 
cardiotoxicity.
Materials
Holoxan vials (Baxter oncology GmbH, Germany) were gifted 
from King Khalid University Hospital drug store, King Saud 
University, Kingdom of Saudi Arabia. Each holoxan vial contains 
1 g IFO in a dry lyophilized powder form. The content of each 
vial was freshly dissolved in sterile water for injection immedi-
ately before injection. Propionyl-L-carnitine (PLC), D-carnitine 
(DC) and Mildronate (MD) were kindly supplied by Dr. Zaven 
Orfalian, Sigma-Tau Pharmaceuticals, Pomezia, Italy. It has been 
supplied as white powder in a non-commercial plastic bottles 
contains 100 g and it was freshly dissolved in normal saline prior 
to injection. All other chemicals used were of the highest analyti-
cal grade.
Animals. Adult male Wistar albino rats, weighing 180–200 g, 
were obtained from the Animal Care Center, College of 
Pharmacy, King Saud University, Riyadh, Saudi Arabia and 
were housed in metabolic cages under controlled environmental   
conditions (25°C and a 12 h light/dark cycle). Animals had free 
access to pulverized standard rat pellet food and tap water. The 
protocol of this study has been approved by Research Ethics 
Committee of College of Pharmacy, King Saud University, 
Riyadh, Kingdom of Saudi Arabia.
Experimental design. Experimental animal model of carni-
tine deficiency was developed according to Paulson and Shug,51 
Whitmer,52 and Tsoko et al.53 In the current study, carnitine deple-
tion was induced in rats by daily intraperitoneal (I.P.) injection 
of DC (250 mg/kg/day) combined with MD (200 mg/kg/day) 
for 10 successive days according to previously published stud-
ies.51-53 Depletion of L-carnitine by DC occurs via an exchange 
of the D-and L-isomers across the cell membrane. Moreover, DC 
possesses an inhibitory effect upon carnitine transferase enzymes 
and competitive inhibitory effect upon L-carnitine uptake.51-53 
Depletion of L-carnitine by MD occurs via inhibition of gamma-
butyrobetaine hydroxylase, a key enzyme in the biosynthesis 
of carnitine.53 Also, Fanconi Syndrome was induced in rats by 
administration of IFO (50 mg/kg/day, I.P.) for 5 successive days 
metabolic pathway of IFO leads to formation of chloroacetyl-CoA 
with the consequent depletion of free CoA-SH.47 L-carnitine is 
known to detoxify acyl-CoA moieties with the formation of acyl-
carnitine and subsequent release of free CoA-SH, thus preserving 
substrates utilization and ATP production in mitochondria. This 
detoxification mechanism leads to an increased secretion of car-
nitine derivatives in urine with subsequent secondary deficiency 
of the molecule.
This progressive decrease of carnitine level in cardiac tissue by 
IFO in carnitine depleted rats was parallel to the marked increase 
in LDH and CK-MB, which may point to the possible consider-
ation of carnitine deficiency as a risk factor in IFO-induced car-
diotoxicity. This aggravated cardiomyopathy could be explained 
on the basis of myocardial carnitine deficiency with subsequent 
impairment of fatty acid oxidation and ATP production. It is well 
known that L-carnitine is an essential cofactor for mitochondrial 
transport and oxidation of long chain fatty acids which are the pre-
ferred substrates for ATP production in normal, well-oxygenated 
adult myocardium.48 Depletion of the heart from carnitine and 
CoA-SH either by IFO, DC-MD or both would impair the beta-
oxidation of long chain fatty acids and pyruvate oxidation with 
the consequent decrease in ATP production and heart contractile 
function. This was supported by the marked decrease of ATP and 
free CoA-SH levels in heart tissues observed in carnitine-depleted 
rats, which renders the cardiac cells vulnerable to damage by IFO.
Table 4. effect of ifosfamide (IFO), propionyl-l-carnitine (pLC), D-
carnitine-mildronate (DC-MD) and their combination on the levels of 
thiobarbituric acid reactive substances (TBARs) and reduced glutathi-
one (Gsh) in rat cardiac tissues.
Treatment groups
TBARS  
(nmol/g wet tissue)
GSH  
(µmol/g wet tissue)
Control 249.60 ± 14.9 0.70 ± 0.02
DC-MD 118.01 ± 14.7* 1.02 ± 0.09
pLC 113.21 ± 9.7* 1.23 ± 0.14*
IFO 449.14 ± 33.9* 0.280 ± 0.03*
IFO plus DC-MD 249.10 ± 33.8*#$ 0.90 ± 0.08$
IFO plus pLC 243.60 ± 24.8# 0.89 ± 0.09#
Rats were randomly divided into 6 different groups of 10 animals each: 
Control, D-carnitine-mildronate (DC-MD, carnitine-depleted group), 
pLC (carnitine supplemented group), IFO, DC-MD plus IFO and pLC plus 
IFO. Carnitine depletion was induced in rats by daily intraperitoneal 
injection of DC (250 mg/kg/day) combined with MD (200 mg/kg/day) 
for 10 successive days. Carnitine supplementation was induced in rats 
by daily intraperitoneal injection of pLC (250 mg/kg/day) for 10 succes-
sive days. Fanconi syndrome was induced in rats by administration of 
IFO (50 mg/kg/day, I.p.) for 5 successive days. IFO-carnitine depleted 
rats were given the same doses of DC-MD for 5 days before and 5 days 
concomitant with IFO. IFO-carnitine supplemented rats were given the 
same doses of pLC for 5 days before and 5 days concomitant with IFO. 
At the end of the treatment protocol, TBARs and Gsh, oxidative stress 
biomarkers, were measured in rat cardiac tissues. Data are presented 
as mean ± s.e.M. (n = 10). *, # and $ indicate significant change from 
control, IFO and DC-MD respectively, at p < 0.05 using ANOVA followed 
by Tukey-Kramer as a post ANOVA test. Data are presented as mean ± 
s.e.M. (n = 10). *, # and $ indicate significant change from control, IFO 
and DC-MD respectively, at p < 0.05 using ANOVA followed by Tukey-
Kramer as a post ANOVA test.272  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 4
reported by Prieto et al.59 In brief, carnitine reacts with acetyl-
CoA forming acetylcarnitine in areaction mediated by carni-
tine acetyltransferase enzyme. The liberated CoA-SH reacts 
with 5,5-dithiobis-(2-nitrobenzoic acid) and forming thiophe-
nolate ion, whose generation is proportional to the amount of 
carnitine and can be measured spectrophotometrically at 412 
nm. Serum, urine and heart tissues were deproteinized with 
equal volume of ice-cold 0.6 M perchloric acid and allowed 
to stand in an ice bath for 10 min. The mixture was centri-
fuged at 1,000x g at 4°C for 5 min. The supernatant was used 
directly for measuring free carnitine after neutralization with 
1.2 M potassium carbonate. For the assay of total carnitine, 
a part of supernatant was mixed with 1 M KOH and incu-
bated at 37°C for 20 min for the hydrolysis of acylcarnitines. 
Carnitine level was computed from a calibration curve for car-
nitine hydrochloride.
Determination of CoA-SH and acetyl-CoA in isolated 
rat heart mitochondria. Rat heart mitochondria were isolated 
according to the procedure of Chappel and Hansford.60 The 
isolation buffer contained 0.21 M mannitol, 0.07 M sucrose, 5 
mM Tris-HCl (pH 7.4) and 1 mM EGTA. In brief, heart tis-
sues were homogenized in mitochondrial isolation buffer and 
centrifuged at 1,000x g for 10 min at 4°C. The resulting super-
natant was decanted and further centrifuged at 1,000x g for 10 
min and the resulting pellet (mitochondria) was resuspended 
in the isolation buffer. Protein concentration of the mitochon-
drial was determined by BioRad protein assay according to 
the method of Bradford.61 Free CoA-SH and acetyl-CoA were 
determined in isolated heart mitochondria using HPLC (Jasco 
Corporation, Ishikawa-Cho, Hachioji, Tokyo, Japan) accord-
ing to Lysiak, et al.62 In brief, mitochondria were mixed with 
ice-cold 6% perchloric acid, centrifuged at 300x g for 5 min 
at 0.5°C, and the resulting supernatant fluid was neutralized 
to pH 6–7, and then injected into HPLC. Chromatographic 
separation was performed using ODS-Hypersil, 150 x 4.6 mm 
I.D., 5 µm column (Supelco SA, Gland, Switzerland). The UV 
detector was operated at 254 nm and set at 0.005. A mobile 
phase of 220 mM potassium phosphate containing 0.05% 
dithioglycol (A) and 98% methanol, 2% chloroform (B) was 
used. The flow rate was 0.6 ml/min and the gradient was as 
follows: at zero time, 94% A and 6% B; at 8 min, 92% A and 
8% B; at 14 min, 87% A and 13% B; at 25 min, 80% A and 
20% B; at 40 min, 55% A and 45% B; at 45 min, 55% A and 
45% B; and at 60 min, 94% A and 6% B.
according to the previously published protocols.7,10,54 To achieve 
the ultimate goals of this study, a total of 60 adult male Wistar 
albino rats were used and divided at random into 6 groups of 10 
animals each. Rats of Group 1 (control group) were received I.P. 
injection of normal saline (2.5 ml/kg/day) for 10 successive days. 
Animals in Group 2 (carnitine-depleted group) were given DC 
(250 mg/kg/day, I.P.) and MD (200 mg/kg/day, I.P.) for 10 suc-
cessive days. Animals in Group 3 (carnitine-supplemented group) 
were given PLC (250 mg/kg/day, I.P.) for 10 successive days. Rats 
of Group 4 (IFO group) were received normal saline for 5 succes-
sive days followed by IFO (50 mg/kg/day, I.P.) for 5 successive 
days. Rats of Group 5 (IFO-carnitine depleted rats) were given 
the same doses of DC-MD as group 2 for 5 days before and 5 
days concomitant with IFO as group 4. Rats of Group 6 (IFO-
carnitine supplemented rats) were given the same doses of PLC as 
Group 3 for 5 days before and 5 days concomitant with IFO as 
Group 4. The following experimental table outlines the sequence 
of studies for each experimental animal model used.
Immediately after the last dose of the treatment protocol, 
24-hour urine was collected for monitoring urinary carnitine 
excretion and carnitine clearance. Animals were then sacrificed 
by decapitation after exposure to ether in a dessicator kept in a 
well-functioning hood and blood samples were obtained. Serum 
was separated for measurement of serum creatinine, blood urea 
nitrogen (BUN) lactate dehydrogenase (LDH), creatine phos-
phokinase iso-enzyme (CK-MB) and total carnitine. Hearts were 
quickly excised, washed with saline, blotted with a piece of filter 
paper and homogenized, in normal saline or 6% perchloric acid 
as indicated in the procedures of measurement of each parameter, 
using a Branson sonifier (250, VWR Scientific, Danbury, CT).
Methods
Assessment of serum creatinine and blood urea nitrogen 
(BUN). Serum creatinine and BUN concentrations were mea-
sured spectrophotometrically according to the methods of 
Fabiny and Ertingshausen55 and Tabacco et al.56 respectively.
Assessment of serum creatine kinase (CK-MB) and lactate 
dehydogenase (LDH) activity. Serum activities of LDH and 
CK-MB were determined according to the methods of Buhl 
and Jackson57 and Wu and Bowers,58 respectively.
Determination of total carnitine in serum, urine and car-
diac tissues. Total carnitine concentrations were determined 
in serum, urine and cardiac tissues according to the method 
Group number
Types and duration of treatments (days)
1 2 3 4 5 6 7 8 9 10
1 Normal saline
2 D-carnitine combined with mildronate
3 propionyl-L-carnitine
4 Normal saline Ifosfamide
5 D-carnitine combined with mildronate
Ifosfamide 
D-carnitine combined with mildronate
6 propionyl-L-carnitine
Ifosfamide 
propionyl-L-carnitinewww.landesbioscience.com  Oxidative Medicine and Cellular Longevity  273
at 532 nm and the concentrations were expressed as nmol 
TBARS/g wet tissue.
Statistical analysis. Differences between obtained values 
(mean ± SEM, n = 10) were carried out by one way analysis 
of variance (ANOVA) followed by the Tukey-Kramer multiple 
comparison test. p ≤ 0.05 was taken as a criterion for a statisti-
cally significant difference.
Conclusions
Data from this study suggest that: (1) serum and urine carnitine 
levels should be viewed as markers that indicate early toxicity and 
should be monitored during IFO-therapy. (2) oxidative stress 
and carnitine deficiency provoke IFO-induced cardiotoxicity. (3) 
carnitine supplementation, using PLC prevents the development 
of IFO-induced cardiotoxicity through improving mitochondrial 
function and antioxidant signalling. It would be worthwhile con-
sidering the addition of PLC as adjunctive therapy to reduce can-
cer chemotherapy related complications.
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Determination of adenosine triphosphate in cardiac tissues. 
Adenosine triphosphate was determined in heart tissues using 
HPLC system (Jasco Corporation, Ishikawa-Cho, Hachioji, 
Tokyo, Japan) according to Botker, et al.63 In brief, heart tis-
sue was homogenized in ice-cold 6% perchloric acid, centri-
fuged at 1,000 rpm for 15 min at 0.5°C and the supernatant 
fluid was injected into HPLC after neutralization to pH 6–7. 
Chromatographic separation was performed at a flow rate of   
1.2 ml/min, using ODS-Hypersil, 150 x 4.6 mm I.D., 5 µm column 
(Supelco SA, Gland, Switzerland) and 75 mM ammonium   
dihydrogen phosphate as mobile phase. The ATP peaks were 
eluted at 3.2 min and the UV detector was operated at 254 nm.
Determination of reduced glutathione and lipid peroxida-
tion in cardiac tissues. The tissue levels of the acid soluble thiols, 
mainly GSH, were assayed spectrophotometrically at 412 nm, 
according to the method of Ellman,64 using a Shimadzu (Tokyo, 
Japan) spectrophotometer. The contents of GSH were expressed 
as mmol/g wet tissue. The degree of lipid peroxidation in car-
diac tissues was determined by measuring thiobarbituric acid 
reactive substances (TBARS) in the supernatant tissue from 
homogenate.65 The homogenates were centrifuged at 3,500 rpm 
and supernatant was collected and used for the estimation of 
TBARS. The absorbance was measured spectrophotometrically 
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